Nasopharyngeal Diseases  >>  Votrient (pazopanib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Votrient (pazopanib) / Novartis, BeiGene
NCT00454142: Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer

Completed
2
33
RoW
pazopanib hydrochloride, GW786034B, Votrient, pharmacological study, pharmacological studies, computed tomography, tomography, computed
National Cancer Institute (NCI)
Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx
04/10
08/10

Download Options